Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan.

Murakami M, Johkoh T, Hayashi S, Ohshima S, Mizuki M, Nakatsuka SI, Tomobe M, Kuroyanagi K, Nakasone A, Nishimoto N.

Mod Rheumatol. 2020 Jan 22:1-9. doi: 10.1080/14397595.2019.1704983. [Epub ahead of print]

PMID:
31829070
2.

Effects of Lactoferrin on Subjective Skin Conditions in Winter: A Preliminary, Randomized, Double-Blinded, Placebo-Controlled Trial.

Oda H, Miyakawa M, Mizuki M, Misawa Y, Tsukahara T, Tanaka M, Yamauchi K, Abe F, Nomiyama T.

Clin Cosmet Investig Dermatol. 2019 Dec 2;12:875-880. doi: 10.2147/CCID.S228153. eCollection 2019.

3.

New criteria for multiple chemical sensitivity based on the Quick Environmental Exposure and Sensitivity Inventory developed in response to rapid changes in ongoing chemical exposures among Japanese.

Hojo S, Mizukoshi A, Azuma K, Okumura J, Mizuki M, Miyata M.

PLoS One. 2019 Apr 26;14(4):e0215144. doi: 10.1371/journal.pone.0215144. eCollection 2019.

4.

Survey on changes in subjective symptoms, onset/trigger factors, allergic diseases, and chemical exposures in the past decade of Japanese patients with multiple chemical sensitivity.

Hojo S, Mizukoshi A, Azuma K, Okumura J, Ishikawa S, Miyata M, Mizuki M, Ogura H, Sakabe K.

Int J Hyg Environ Health. 2018 Sep;221(8):1085-1096. doi: 10.1016/j.ijheh.2018.08.001. Epub 2018 Aug 14.

PMID:
30115513
5.

Low Variability in Peak Expiratory Flow Predicts Successful Inhaled Corticosteroid Step-Down in Adults with Asthma.

Tsurikisawa N, Oshikata C, Sato T, Kimura G, Mizuki M, Tsuburai T, Shoji S, Saito H, Shimoda T.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):972-979. doi: 10.1016/j.jaip.2017.10.036. Epub 2017 Dec 6.

PMID:
29221918
6.

A New Approach for Determining Short-Term, Objective Prognostic Predictive Methods for Terminal Cancer Patients Based on the Change Point of Laboratory Test Values.

Niki K, Okamoto Y, Tabata Y, Tsugane M, Murata T, Mizuki M, Matsumura Y, Takagi T, Uejima E.

J Palliat Med. 2018 Apr;21(4):529-532. doi: 10.1089/jpm.2017.0233. Epub 2017 Nov 17.

PMID:
29148861
7.

Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan.

Fujimoto S, Koga T, Kawakami A, Kawabata H, Okamoto S, Mizuki M, Yano S, Ide M, Uno K, Yagi K, Kojima T, Mizutani M, Tokumine Y, Nishimoto N, Fujiwara H, Nakatsuka SI, Shiozawa K, Iwaki N, Masaki Y, Yoshizaki K.

Mod Rheumatol. 2018 Jan;28(1):161-167. doi: 10.1080/14397595.2017.1366093. Epub 2017 Sep 7.

PMID:
28880697
8.

Development and evaluation of an electromagnetic hypersensitivity questionnaire for Japanese people.

Hojo S, Tokiya M, Mizuki M, Miyata M, Kanatani KT, Takagi A, Tsurikisawa N, Kame S, Katoh T, Tsujiuchi T, Kumano H.

Bioelectromagnetics. 2016 Sep;37(6):353-72. doi: 10.1002/bem.21987. Epub 2016 Jun 21.

9.

Gfi1, a transcriptional repressor, inhibits the induction of the T helper type 1 programme in activated CD4 T cells.

Suzuki J, Maruyama S, Tamauchi H, Kuwahara M, Horiuchi M, Mizuki M, Ochi M, Sawasaki T, Zhu J, Yasukawa M, Yamashita M.

Immunology. 2016 Apr;147(4):476-87. doi: 10.1111/imm.12580. Epub 2016 Feb 9.

10.

Risk factors for cytarabine-induced cutaneous toxicity in patients with haematological malignancies.

Morio K, Mizuki M, Sozu T, Uejima E.

Chemotherapy. 2014;60(3):168-73. doi: 10.1159/000371839. Epub 2015 Mar 19.

PMID:
25823612
11.

Quantitative polymerase chain reaction analysis with allele-specific oligonucleotide primers for individual IgH VDJ regions to evaluate tumor burden in myeloma patients.

Sata H, Shibayama H, Maeda I, Habuchi Y, Nakatani E, Fukushima K, Fujita J, Ezoe S, Tadokoro S, Maeda T, Mizuki M, Kosugi S, Nakagawa M, Ueda S, Iida M, Tokumine Y, Azenishi Y, Mitsui H, Oritani K, Kanakura Y.

Exp Hematol. 2015 May;43(5):374-381.e2. doi: 10.1016/j.exphem.2015.01.002. Epub 2015 Jan 13.

PMID:
25591497
12.

Development of structured clinical process model of dementia.

Tsuru S, Mizuki M, Wako F, Omori M, Nakayama T.

Stud Health Technol Inform. 2014;205:672-6.

PMID:
25160271
13.

[The development history and future perspective of molecularly targeted therapy].

Mizuki M, Kanakura Y.

Nihon Rinsho. 2014 Jun;72(6):997-1003. Review. Japanese.

PMID:
25016795
14.

[Effect of the administration of zoledronic acid on life expectancy in patients with multiple myeloma with or without renal impairment].

Morio K, Tsugane M, Mizuki M, Uejima E.

Gan To Kagaku Ryoho. 2014 Apr;41(4):461-5. Japanese.

PMID:
24743361
15.

[A case of chronic active Epstein-Barr virus infection associated with recurrent cerebellar ataxia and skin eruptions].

Araki K, Okuno T, Honorat JA, Kinoshita M, Takahashi MP, Mizuki M, Kitagawa K, Mochizuki H.

Rinsho Shinkeigaku. 2013;53(2):119-24. Japanese.

PMID:
23470892
16.

[Pathogenesis, diagnosis and treatment of mastocytosis].

Mizuki M, Kanakura Y.

Nihon Rinsho. 2012 Apr;70 Suppl 2:337-41. Japanese. No abstract available.

PMID:
23133978
17.

Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic.

Nishida T, Hiramatsu N, Mizuki M, Nagatomo I, Kida H, Tazumi K, Shinzaki S, Miyazaki M, Yakushijin T, Tatsumi T, Iijima H, Kiso S, Kanto T, Tsujii M, Takehara T.

Hepatol Res. 2013 Apr;43(4):339-46. doi: 10.1111/j.1872-034X.2012.01073.x. Epub 2012 Aug 6.

PMID:
22882474
18.

[A case of primary malignant lymphoma of the prostate].

Kishimoto N, Takao T, Yamamoto K, Tsujihata M, Nonomura N, Yamamoto M, Mizuki M, Hara T.

Hinyokika Kiyo. 2011 Aug;57(8):445-9. Review. Japanese.

19.

C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.

Satoh Y, Matsumura I, Tanaka H, Harada H, Harada Y, Matsui K, Shibata M, Mizuki M, Kanakura Y.

Leukemia. 2012 Feb;26(2):303-11. doi: 10.1038/leu.2011.202. Epub 2011 Aug 12.

PMID:
21836608
20.

Constitutively active FGFR3 with Lys650Glu mutation enhances bortezomib sensitivity in plasma cell malignancy.

Otsuka M, Mizuki M, Fujita J, Kang S, Kanakura Y.

Anticancer Res. 2011 Jan;31(1):113-22.

PMID:
21273588
21.

Myeloid neoplasm-related gene abnormalities differentially affect dendritic cell differentiation from murine hematopoietic stem/progenitor cells.

Fujita J, Mizuki M, Otsuka M, Ezoe S, Tanaka H, Satoh Y, Fukushima K, Tokunaga M, Matsumura I, Kanakura Y.

Immunol Lett. 2011 Apr 30;136(1):61-73. doi: 10.1016/j.imlet.2010.12.006. Epub 2011 Jan 13.

PMID:
21237204
22.

Intravascular lymphomatosis initially suspected from uterine cytology: a case report.

Nakamichi I, Shimazu K, Ikeda J, Yamauchi A, Ishiko J, Mizuki M, Kanakura Y, Aozasa K.

Acta Cytol. 2009 Mar-Apr;53(2):198-200.

PMID:
19365976
23.

[Diagnosis of multiple chemical sensitivity by chemical compounds exposure tests].

Hasegawa M, Ohtomo M, Mizuki M, Akiyama K.

Arerugi. 2009 Feb;58(2):112-8. Japanese.

PMID:
19329873
24.

AML1/RUNX1 works as a negative regulator of c-Mpl in hematopoietic stem cells.

Satoh Y, Matsumura I, Tanaka H, Ezoe S, Fukushima K, Tokunaga M, Yasumi M, Shibayama H, Mizuki M, Era T, Okuda T, Kanakura Y.

J Biol Chem. 2008 Oct 31;283(44):30045-56. doi: 10.1074/jbc.M804768200. Epub 2008 Aug 7.

25.

[Trial of "Huber Plus" in outpatients with chemotherapy by blood port system].

Matsumura N, Tazumi K, Kouji K, Kondo M, Mizuki M.

Gan To Kagaku Ryoho. 2008 Mar;35(3):539-41. Japanese.

PMID:
18347413
26.

[Our experience using "Huber Plus" needles in our infusion center].

Tazumi K, Kouji K, Matsumura N, Nabetani Y, Kondo M, Tomono K, Mizuki M.

Gan To Kagaku Ryoho. 2008 Jan;35(1):105-8. Japanese.

PMID:
18195536
27.

Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.

Matsumura I, Mizuki M, Kanakura Y.

Cancer Sci. 2008 Mar;99(3):479-85. doi: 10.1111/j.1349-7006.2007.00717.x. Epub 2008 Jan 2. Review.

28.

[Incident surveillance in outpatients treated with hepatic arterial infusion (HAI) chemotherapy with infusion pump].

Kouji K, Tazumi K, Matsumura N, Kondo M, Mizuki M.

Gan To Kagaku Ryoho. 2007 Dec;34(13):2263-6. Japanese.

PMID:
18079627
29.

An indolent subtype of "intravascular lymphoma": A case with a 3-year history of LDH elevation.

Ishiko J, Mizuki M, Yasumi M, Ujiie H, Nakamichi I, Aozasa K, Kanakura Y.

Leuk Lymphoma. 2007 Sep;48(9):1872-4. No abstract available.

PMID:
17786729
30.

[Present situation and problems of the ordering system type infusion center].

Kondo M, Tazumi K, Kouji K, Matsumura N, Takegami M, Kurokawa N, Kanakura Y, Noguchi S, Mizuki M.

Gan To Kagaku Ryoho. 2007 Aug;34(8):1264-6. Japanese.

PMID:
17687209
31.

Unicentric and multicentric Castleman's disease.

Enomoto K, Nakamichi I, Hamada K, Inoue A, Higuchi I, Sekimoto M, Mizuki M, Hoshida Y, Kubo T, Aozasa K, Hatazawa J.

Br J Radiol. 2007 Jan;80(949):e24-6.

PMID:
17267466
32.

Encapsulation of small molecules by a cavitand porphyrin self-assembled via quadruple hydrogen bonds.

Nakazawa J, Mizuki M, Shimazaki Y, Tani F, Naruta Y.

Org Lett. 2006 Sep 14;8(19):4275-8.

PMID:
16956205
33.

The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway.

Yu M, Luo J, Yang W, Wang Y, Mizuki M, Kanakura Y, Besmer P, Neel BG, Gu H.

J Biol Chem. 2006 Sep 29;281(39):28615-26. Epub 2006 Jul 27.

34.

Endolymphatic hydrops as a cause of audio-vestibular manifestations in relapsing polychondritis.

Murata J, Horii A, Tamura M, Mitani K, Mizuki M, Kubo T.

Acta Otolaryngol. 2006 May;126(5):548-52.

PMID:
16698708
35.

Roles of tyrosine residues 845, 892 and 922 in constitutive activation of murine FLT3 kinase domain mutant.

Ishiko J, Mizuki M, Matsumura I, Shibayama H, Sugahara H, Scholz G, Serve H, Kanakura Y.

Oncogene. 2005 Dec 8;24(55):8144-53.

PMID:
16091740
36.

Size-selective and reversible encapsulation of single small hydrocarbon molecules by a cavitand-porphyrin species.

Nakazawa J, Hagiwara J, Mizuki M, Shimazaki Y, Tani F, Naruta Y.

Angew Chem Int Ed Engl. 2005 Jun 13;44(24):3744-6. No abstract available.

PMID:
15880696
37.

GATA transcription factors inhibit cytokine-dependent growth and survival of a hematopoietic cell line through the inhibition of STAT3 activity.

Ezoe S, Matsumura I, Gale K, Satoh Y, Ishikawa J, Mizuki M, Takahashi S, Minegishi N, Nakajima K, Yamamoto M, Enver T, Kanakura Y.

J Biol Chem. 2005 Apr 1;280(13):13163-70. Epub 2005 Jan 25.

38.

Distinct role for c-kit receptor tyrosine kinase and SgIGSF adhesion molecule in attachment of mast cells to fibroblasts.

Koma Y, Ito A, Watabe K, Hirata T, Mizuki M, Yokozaki H, Kitamura T, Kanakura Y, Kitamura Y.

Lab Invest. 2005 Mar;85(3):426-35.

39.

Notch signals inhibit the development of erythroid/megakaryocytic cells by suppressing GATA-1 activity through the induction of HES1.

Ishiko E, Matsumura I, Ezoe S, Gale K, Ishiko J, Satoh Y, Tanaka H, Shibayama H, Mizuki M, Era T, Enver T, Kanakura Y.

J Biol Chem. 2005 Feb 11;280(6):4929-39. Epub 2004 Nov 24.

40.

Roles for c-Myc in self-renewal of hematopoietic stem cells.

Satoh Y, Matsumura I, Tanaka H, Ezoe S, Sugahara H, Mizuki M, Shibayama H, Ishiko E, Ishiko J, Nakajima K, Kanakura Y.

J Biol Chem. 2004 Jun 11;279(24):24986-93. Epub 2004 Apr 2.

41.

Footwear exchange has no influence on the incidence of febrile neutropenia in patients undergoing chemotherapy for hematologic malignancies.

Sugahara H, Mizuki M, Matsumae S, Nabetani Y, Kikuchi M, Kanakura Y.

Infect Control Hosp Epidemiol. 2004 Jan;25(1):51-4.

PMID:
14756220
42.

Oncogenic receptor tyrosine kinase in leukemia.

Mizuki M, Ueda S, Matsumura I, Ishiko J, Schwäble J, Serve H, Kanakura Y.

Cell Mol Biol (Noisy-le-grand). 2003 Sep;49(6):907-22. Review.

PMID:
14656048
44.

Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications.

Saeki Y, Mima T, Ishii T, Ogata A, Kobayashi H, Ohshima S, Ishida T, Tabunoki Y, Kitayama H, Mizuki M, Katada Y, Asaoku H, Kitano M, Nishimoto N, Yoshizaki K, Maeda M, Kon S, Kinoshita N, Uede T, Kawase I.

Br J Haematol. 2003 Oct;123(2):263-70.

PMID:
14531907
45.

Constitutively activated Rho guanosine triphosphatases regulate the growth and morphology of hairy cell leukemia cells.

Zhang X, Machii T, Matsumura I, Ezoe S, Kawasaki A, Tanaka H, Ueda S, Sugahara H, Shibayama H, Mizuki M, Kanakura Y.

Int J Hematol. 2003 Apr;77(3):263-73.

PMID:
12731670
46.

Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.

Ueda S, Ikeda H, Mizuki M, Ishiko J, Matsumura I, Tanaka H, Shibayama H, Sugahara H, Takai E, Zhang X, Machii T, Kanakura Y.

Int J Hematol. 2002 Dec;76(5):427-35.

PMID:
12512837
47.

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.

Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Böhmer FD, Müller-Tidow C, Berdel WE, Serve H.

Blood. 2003 Apr 15;101(8):3164-73. Epub 2002 Dec 5.

PMID:
12468433
48.

[Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].

Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.

Dtsch Med Wochenschr. 2002 Oct 18;127(42):2195-200. German.

PMID:
12397548
49.

Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation.

Hashimoto K, Matsumura I, Tsujimura T, Kim DK, Ogihara H, Ikeda H, Ueda S, Mizuki M, Sugahara H, Shibayama H, Kitamura Y, Kanakura Y.

Blood. 2003 Feb 1;101(3):1094-102. Epub 2002 Sep 12.

PMID:
12393643
50.

Supplemental Content

Loading ...
Support Center